Abstract
Acalabrutinib, a second-generation and more selective Bruton’s tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group.
Original language | English (US) |
---|---|
Pages (from-to) | 43-47 |
Number of pages | 5 |
Journal | Journal of Immunotherapy and Precision Oncology |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - May 2022 |
Keywords
- acalabrutinib
- atrial fibrillation
- cardiac toxicities
- chronic lymphocytic leukemia
- hypertension
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
- Cancer Research